https://www.******.com.au/media/the-aussie-medtech-to-partner-with-astrazeneca?videoId=5043
AstraZeneca approached ResApp a couple of months ago.
When lung cancer patients take AstraZeneca drugs our app will give them vital feedback about how the patient is progressing at home after therapy. The app just needs to be near the patient. This Builds vital info for the regulatory processes AstraZeneca is currently in with their drugs.
So with this product we have three partnerships announced recently, this with AstraZeneca, HealthEngine and Queensland Diabetes with SleepCheck. Tony describes these as ‘foundational partnerships’ to enhance the commercialisation process.
Tony describes us as an international company focusing in Europe with a number of hires there over the last 6 months. Talking to major potential partners in Europe and globally.
Cash at hand is good, they are frugal with it. Qtly report at the end of next week. There are roughly 4 quarters of cash available at present. By then the company will be generating ‘material’ revenues.
This sounds very good for our future prospects and makes up for the virtual silence from over the last few months.
Ann: AstraZeneca to use new ResApp software in clinical study, page-72
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #